hepatocellular carcinoma
Conditions
Interventions
Three groups:30Gy/10 fractions vs 40Gy/10 vs 50Gy/10 fractions
Sponsors
Guangxi Medical University Cancer Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. aged 18-70 years; 2. Histologically diagnosed hepatocellular carcinoma, or that meets the criteria of the American association for the study of hepatology for the clinical diagnosis of hepatocellular carcinoma; 3. Liver function child-pugh grade A; 4. ECOG 0-1; 5. Expected survival of > for 3 months; 6. Hemoglobin >=90g/L; Neutrophil absolute count (ANC) >=1.5x10^9/L; Platelet >60x10^9/L; ALT, AST 3 ULN or less; Serum total bilirubin =30g/L; 7. Unwilling to accept or unable to tolerate first-line sorafenib or lenvastinib treatment; 8. The patient and its authorized legal representative understand and agree to sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) previous or co-existing malignancy, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; (2) previously received anti-pd-1 drugs or drugs that stimulate or synergistically inhibit T cell receptor; (3) received radiotherapy within 6 months before administration; (4) an active autoimmune disease requiring systemic treatment occurred in the 2 years prior to enrollment; (5) known severe allergic reaction to pd-1 monoclonal antibody; (6) an active infection requiring systemic treatment; (7) patients with a clear tendency to gastrointestinal bleeding; (8) hyperarteriovenous/venous thrombotic events occurred within one year; (9) persons with a history of substance abuse and unable to quit or mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;Side effects; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Overall survival; | — |
Contacts
Public ContactTING-SHI SU
Guangxi Medical University Cancer Hospital
Outcome results
None listed